DAM
LPCN icon

DLD Asset Management’s Lipocine LPCN Stock Holding History

DLD Asset Management’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-7,000
Closed -$195K – 111
2017
Q4 		$409K Sell
7,000
-16,606
-70% -$1.03M 0.03% 59
2017
Q3 		$1.59M Buy
23,606
+12,912
+121% +$934K 0.16% 42
2017
Q2 		$730K Buy
+10,694
New +$698K 0.1% 50

Other funds holding LPCN

JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

DLD Asset Management's LPCN Position: Q1 2018 in Review

DLD Asset Management sold out of Lipocine (LPCN) in Q1 2018, closing a stake of 7,000 shares — an estimated $195K sold.

DLD Asset Management first reported a position in LPCN in Q2 2017 and held it in 3 quarters. The position peaked at $1.59M in Q3 2017. 27 funds tracked by Wall St. Rank hold LPCN as of Q1 2018.

  • DLD Asset Management reported no remaining Lipocine position as of Q1 2018 after selling out during the quarter.
  • DLD Asset Management sold 7,000 Lipocine shares in Q1 2018, an estimated $195K.
  • DLD Asset Management first reported a position in Lipocine in Q2 2017 and held it in 3 quarters.
  • DLD Asset Management's Lipocine position peaked at $1.59M in Q3 2017.
  • 27 funds tracked by Wall St. Rank held Lipocine as of Q1 2018.

Based on DLD Asset Management's 13F filing for Q1 2018, filed 14 May 2018.